💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ranitidine

CHEMBL1790041 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
2-3 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
314.4 g/mol
LogP
0.3
Phase
4

A histamine H2 blocker that reduces stomach acid production, formerly widely used to treat GERD, ulcers, and heartburn. It has largely been withdrawn from markets due to concerns about a potential contaminant that may form during storage.

น้ำหนักโมเลกุล

314.4050 g/mol

LogP

0.30

TPSA

112.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Gastroesophageal Reflux Disease Multiple Sclerosis Stroke Obesity Lymphoma Hypertension Breast Cancer Heart Failure Prostate Cancer Colorectal Cancer Leukemia

หมวดหมู่ยา

A — A - Alimentary Tract and Metabolism

กลไกการออกฤทธิ์

Competitive H2 receptor antagonist.

Pharmacokinetics (PK)

Half-Life 2-3 hours

Pharmacodynamics (PD)

กลไก

Competitive H2 receptor antagonist.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1

                

                

                
                

                    
InChI

                    
InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C13H22N4O3S

                    

                    
                    

                        
HBD / HBA

                        
2 / 7

                    

                    
                    

                        
พันธะที่หมุนได้

                        
9

                    

                    
                    
                    

                        
อะตอมหนัก

                        
21

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            HRH2 (Histamine H2 Receptor)
                            Antagonist
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Ranitidine + Warfarin
                            
                        

                        
                        
Ranitidine can modestly increase warfarin plasma levels and INR by inhibiting CYP2C9-mediated warfarin metabolism, though the magnitude is smaller than with cimetidine.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Ranitidine + Cephalexin
                            
                        

                        
                        
Ranitidine may reduce the absorption rate of cephalexin by raising gastric pH, but overall bioavailability is not substantially altered, making this interaction clinically insignificant.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Ranitidine + Metformin
                            
                        

                        
                        
Ranitidine competitively inhibits OCT2-mediated renal tubular secretion of metformin, modestly increasing metformin plasma concentrations.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Ranitidine + Diazepam
                            
                        

                        
                        
Ranitidine can modestly increase diazepam bioavailability by raising gastric pH and weakly inhibiting hepatic CYP2C19-mediated diazepam metabolism.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Ranitidine + Phenytoin
                            
                        

                        
                        
Ranitidine may slightly increase phenytoin bioavailability through modest inhibition of CYP2C9, though the interaction is less significant than with cimetidine.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
A histamine H2 blocker that reduces stomach acid production, formerly widely used to treat GERD, ulcers, and heartburn. It has largely been withdrawn from markets due to concerns about a potential contaminant that may form during storage.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitive H2 receptor antagonist.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Ranitidine: Half-life: 2-3 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Ranitidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Metformin
                            Small molecule
                        
                        
                        
                            Omeprazole
                            Small molecule
                        
                        
                        
                            Pantoprazole
                            Small molecule
                        
                        
                        
                            Lansoprazole
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1790041.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3001055.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.